Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Lymphoma 7Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, AIDS-Related 2Glioma 2Burkitt Lymphoma 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Intraocular Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Filgrastim 5fludarabine phosphate 4Cyclophosphamide 4Antilymphocyte Serum 4Mycophenolic Acid 3Carboplatin 3pembrolizumab 2Tacrolimus 2Sirolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2Methotrexate 2Drug Therapy 2Cyclosporine 2Busulfan 2valspodar 1tremelimumab 1thymoglobulin 1temsirolimus 1tanespimycin 1sargramostim 1poly ICLC 1liposomal doxorubicin 1ixabepilone 1interferon-alfa-1b 1glutamic acid diethyl ester 1fludarabine 1etoposide phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Lomustine × Lymphoid × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡